Analysis of K-Ras Interactions by Biotin Ligase Tagging

Christopher Ritchie1, Andrew Mack1, Logan Harper1

  • 1Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, OR, U.S.A.

Abstract

Insights

This study maps the K-Ras interaction network using biotin ligase tagging, identifying 748 proteins and 56 partners in pancreatic cancer cells. This reveals key proteins involved in cancer, aiding biomarker discovery.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Proteomics

Background:

  • Mutations in human K-Ras 4B (K-Ras) G protein are implicated in a substantial fraction of human cancers.
  • A comprehensive understanding of K-Ras protein interactions is currently lacking.
  • This study aims to characterize the K-Ras interaction network.

Purpose of the Study:

  • To identify and characterize proteins that interact with K-Ras.
  • To investigate differences in K-Ras interactions based on protein variants.
  • To discover potential cancer biomarkers associated with K-Ras.

Main Methods:

  • Utilized a biotin ligase-tagging approach for proximity-dependent biotinylation of K-Ras.
  • Employed mass spectrometry (MS) sequencing for identification of biotinylated proteins.
  • Analyzed K-Ras interaction partners in transfected cells and pancreatic cancer cells.

Main Results:

  • Identified a total of 748 biotinylated proteins in cells expressing biotin ligase-tagged K-Ras variants.
  • Observed significant differences in protein interactions between membrane-associated K-Ras variants and a farnesylation-defective mutant.
  • Discovered 56 K-Ras interaction partners in pancreatic cancer cells, predominantly cytoskeletal and plasma membrane proteins, many of which are potential cancer biomarkers.

Conclusions:

  • Biotin ligase tagging is an effective and efficient method for mapping K-Ras interaction networks.
  • The identified K-Ras interactome provides insights into cancer mechanisms.
  • The findings highlight potential novel cancer biomarkers and therapeutic targets.